Cooper-Standard Holdings Inc. (CPS) Q3 2025 Earnings Call Transcript

Good morning, ladies and gentlemen, and welcome to the Cooper-Standard Third Quarter 2025 Earnings Conference Call. As a reminder, this conference call is being recorded, and the webcast will be ...
Le Lézard

Mallinckrodt to Present Data on Terlipressin at the 2025 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of four posters in patients with hepatorenal syndrome (HRS), including a Poster of Distinction, at The ...
Le Lézard

ERI's John Shegerian Shares the Critical Importance of Sustainability with University of Texas at Austin Business Students

John Shegerian, Chairman and CEO of ERI, the nation's leading material resource recovery, ITAD, mobility and data destruction/processing provider, last week delivered guest lectures to three ...

Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG ...

Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically ...

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company’s registrational KYSA-6 ...